General Child Neurology
Acute cerebellar ataxia in children
Oct. 29, 2024
Worddefinition
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
Multiple sclerosis: biological differences in children and adults
- Updated 04.30.2024
- Released 10.17.2012
- Expires For CME 04.30.2027
Multiple sclerosis: biological differences in children and adults
Introduction
Overview
Multiple sclerosis is a chronic inflammatory autoimmune demyelinating disease affecting the central nervous system. Although rare in the pediatric population, its onset in the youth population is becoming increasingly recognized. Because the developing nervous system is a particularly susceptible target of the immune system, children with multiple sclerosis represent a group in whom a strategy of relapse prevention and maintenance therapy may prevent long-term disability. The behavior of the immune system in children with multiple sclerosis appears to be distinct from that that of other autoimmune disorders. The potential for enhanced neural plasticity in children provides a unique opportunity for a meaningful recovery along with long-term disability prevention. Furthermore, there is evidence suggesting that molecular mimicry may play a causal role in a subset of early-onset multiple sclerosis groups (51). This may be associated with an Epstein Barr virus infection or other viral infection as a cause of the disease (51). In addition, glial cell adhesion molecule expressed on some glial cells, such as astrocytes and oligodendrocytes, have been associated with the presence EBNA1 antibodies. They were found in the B-cell clonal expansions from the CSF of patients with early multiple sclerosis who presented with clinically isolated syndrome versus an acute relapse of this disease.
Key points
|
• Epidemiological data support the etiology of multiple sclerosis as a parainfectious process, such as Epstein-Barr virus infection. | |
|
• Development of chronic inflammation occurs in susceptible individuals on the basis of the individual’s immune responses to antigenic stimuli. | |
|
• The central nervous system provides targets that result in chronic inflammatory responses, some of which are very severe in children. | |
|
• Age is an independent variable that, at least in part, determines the progression of disease in multiple sclerosis. | |
|
• Monitoring effective treatments with appropriate biomarkers is important in preventing long-term disability. |
Description
Definition and epidemiology. Multiple sclerosis is a chronic inflammatory, immune-mediated disorder of the central nervous system that starts in early adulthood in the majority of cases but can occur in childhood and adolescence in approximately 3% to 5% of cases (75). The earliest described age of onset is 24 months of age (71). The etiology is not known, though a parainfectious or other environmental immune response at onset may initiate cross-reactive nerve or myelin immunity that becomes self-sustained in individuals’ genetic susceptibilities. The HLA-DRB1 genetic locus and environmental factors, such as vitamin D levels, Epstein-Barr virus infection, and smoking, influence the risk and development of both pediatric and adult multiple sclerosis (09; 57; 59; 28; 87). Overall, the pooled incidence of multiple sclerosis is 2 per 100,000 per year (83). The pooled global incidence of pediatric multiple sclerosis is 0.87 per 100,000 per year (15). A total of 2.8 million people had multiple sclerosis in 2020, indicating a 30% increase in prevalence since 2013 that was possibly attributed to diagnosis at an earlier onset of disease, better diagnostic capabilities, and most likely, longer survival among individuals diagnosed with multiple sclerosis (83).
Pathology. Multiple sclerosis is characterized by chronic inflammation with demyelination as well as axonal degeneration and loss of oligodendrocytes. It involves gliosis, remyelination, and synaptic changes (42; 88; 30). Inflammation is often multifocal but can be diffuse and focal at times during the course of disease. Demyelination is not limited to the white matter but also appears in cortical regions, and inflammation is present in the meninges in early multiple sclerosis (53). In addition, grey matter loss with cortical and thalamic neuronal loss occurs from the onset of disease (80; 79; 19). Therefore, the central nervous system inflammatory process contributes to a slowly progressive disease course that may represent cumulative neuronal and synaptic loss in addition to other factors, including early-onset axonal degeneration (42; 88; 30).
Risk factors
Genetics. The HLA-DRB1 locus is the most important genetic risk factor for developing multiple sclerosis, conferring increased susceptibility for whites (-DRB1*1501) and African Americans (-DRB1*1503) (66). The HLA DRB1*15:01 haplotype is carried by 25% to 30% of the population in northern Europe and the United States (86). It may also contribute to an approximately 3-fold increase in the risk of multiple sclerosis susceptibility in childhood (-DRB1*15) (13; 46). Conversely, variations in the HLA-A gene confer decreased risk susceptibility for developing multiple sclerosis (46). Other genetic loci, including IL2RA and IL7R, have been identified in genome-wide association studies as being important for multiple sclerosis susceptibility (44; 46). Furthermore, these genetic risk loci are associated with increased propensity to childhood onset multiple sclerosis (78). Although other genome-wide association studies have shown over 4000 single nucleotide polymorphisms, the two loci found in the most recent study by the International Multiple Sclerosis Genetics Consortium showed evidence of enrichment of CLECL1 in microglial cells suggestive of microglial activation in the central nervous system cortex. In addition, it is enriched in peripheral immune cells, including T, B, NK, and dendritic cells arising from the thymus, which is a tissue considered important for the peripherally mediated arm of autoimmunity in multiple sclerosis and other autoimmune disorders (45). However, among all the single nucleotide polymorphisms identified, the genetic effects of any locus on the risk for developing multiple sclerosis are significantly less potent compared to the major histocompatibility complex (66; 24; 46). Furthermore, there is an increased propensity among patients with multiple sclerosis of developing young adult-onset Hodgkin lymphoma, suggesting a shared genetic risk factor for both diseases and implicating a genetic cause that may be linked to an Epstein-Barr virus etiology (58). The role of epigenetics in multiple sclerosis has not been clearly defined. However, it is possible that epigenetic mechanisms, including DNA methylation and histone modification, may modulate the interaction between genes and the environment and explain some of the differences in multiple sclerosis susceptibility (17). They may also account for some of the differences in disease activity, including the effects of histone modification on remyelination through regulation of oligodendrocyte differentiation, a process that may be impaired in older individuals (73).
Environmental factors. There are differences in the prevalence of multiple sclerosis in different parts of the world. The frequency in Europe, North America, and Australia is high compared to Asia and tropical regions. The incidence correlates positively with increased distance from the latitude of the equator, and this cannot be fully explained by genetic differences (04; 05). There is also a risk modification for developing multiple sclerosis that is associated with geographic migration, with risk dependent on both age at the time of migration and direction of migration. The younger the age of migration, the more likely it is that the incidence of multiple sclerosis in migrants is closer to the multiple sclerosis incidence of their residing destination (04). Environmental factors in children as well as in adults, especially Epstein-Barr virus infection and vitamin D levels, contribute significantly to multiple sclerosis risk and may explain some of the geographic variation and differences associated with migration (04).
The causal mechanism of Epstein-Barr virus playing a critical role in determining the risk for developing multiple sclerosis has been found in a study published in Science. In a cohort of 10 million young adults on active duty in the United States military, 955 were diagnosed with multiple sclerosis after developing an Epstein-Barr virus infection (12). This study reported that there is a 32-fold increased risk of developing multiple sclerosis (hazard ratio for multiple sclerosis with Epstein-Barr virus seroconversion versus seronegativity was 32.4, with a 95% confidence interval of 4.3 to 245.3 and p < 0.002) over a 20-year period. There was no other virus, including cytomegalovirus, shown to increase the risk of developing multiple sclerosis in this patient population. This included cytomegalovirus, which did not appear to be associated with an increased risk of developing multiple sclerosis in this population cohort. Epstein-Barr virus infection in advance of multiple sclerosis onset was found in nearly all of the 801 cases diagnosed with multiple sclerosis matched with their cohorts, with the exception of one individual patient. However, more than 95% of healthy adults have Epstein-Barr virus seropositivity, whereas only 0.1% to 0.5% of adults develop multiple sclerosis. Therefore, Epstein-Barr virus infection alone is not enough to cause the disease. Many studies have researched other factors that modify this Epstein-Barr virus–associated multiple sclerosis risk. The U.S. Network of Pediatric Multiple Sclerosis Centers found that Epstein-Barr virus seropositive children are at increased risk of having pediatric-onset multiple sclerosis compared to Epstein-Barr virus seronegative children (OR: 9.89, 95% CI: 6.21–15.73) (91). They found that there is an additive and multiplicative interaction between childhood Epstein-Barr virus infection and HLA-DRB1*15. An additive interaction was also seen with childhood Epstein-Barr virus infections and the presence of GG (rs2104286) in CD86.
The association between Epstein-Barr virus and increased multiple sclerosis susceptibility is established, but the association with other viral and bacterial antigens proposed to be important triggers in the etiology of multiple sclerosis, including Chlamydia pneumoniae and human herpes virus (HHV) 6, is debatable. Antibodies to C pneumoniae detected in the CSF of 28% of pediatric patients with multiple sclerosis comprised less than 1% of total intrathecal IgG, suggesting their presence may be part of a polyspecific oligoclonal response (70). The presence of C pneumoniae DNA in the CSF of adult patients with multiple sclerosis has not been confirmed (14). HHV-6 was found in autopsy specimens of multiple sclerosis lesions, and there was evidence of HHV-6 infection in the serum and CSF of patients with multiple sclerosis. However, given that HHV-6 is ubiquitous, it is unlikely to explain the epidemiology of multiple sclerosis (04). An age-matched case-control study showed that pediatric patients with multiple sclerosis who were seropositive for Epstein-Barr nuclear antigen-1 had an increased risk for multiple sclerosis (OR: 3.78, 95% CI: 1.52–9.38, p = 0.004), whereas those with remote infection with cytomegalovirus had a decreased risk of multiple sclerosis (OR: 0.27, 95% CI: 0.11-0.67, p = 0.004) (87). Infection with herpes simplex virus 1 was associated with decreased susceptibility for multiple sclerosis in those who were positive for the DRB1*15 allele (OR: 0.07, 95% CI: 0.02–0.32, p = 0.001) and increased susceptibility in those who were negative for the allele (OR: 4.11, 95% CI: 1.17–14.37, p < 0.05). A multinational observational study of age- and region-matched pediatric patients with multiple sclerosis and non-demyelinating neurologic disorder control participants showed that 86% of pediatric patients with multiple sclerosis, compared with 64% of controls, had positive Epstein-Barr nuclear antigen-1 and viral capsid antigen consistent with remote Epstein-Barr virus infection, regardless of geographical location (p = 0.025, adjusted for multiple comparisons). However, the patients with multiple sclerosis did not show any difference from controls in the seroprevalence of IgG antibodies directed against cytomegalovirus, herpes simplex virus, parvovirus B19, or varicella zoster virus (09a).
Vitamin D insufficiency is associated with increased risk for multiple sclerosis. Based on a case control study using the Department of Defense Serum Repository database, there was a 41% reduction in multiple sclerosis risk in whites for each 50 nmol/L increase in 25-hydroxy vitamin D (relative risk 0.59, 95% confidence interval 0.36-0.97, p = 0.04) (63). Low levels of vitamin D are associated with increased disease activity. In a retrospective study, pediatric patients with multiple sclerosis or clinically isolated syndrome with lower serum 25-hydroxy vitamin D3 levels had an increased relapse rate, with each 10 ng/mL increase in the adjusted 25-hydroxy vitamin D3 level associated with a decrease in the rate of future relapses by one third (incidence rate ratio 0.66, 95% confidence interval 0.46-0.95, p = 0.024) (59). In a study of patients with multiple sclerosis treated with interferon beta-1b after a clinically isolated syndrome, a 20 ng/mL increase in the average serum 25-hydroxy vitamin D levels during the first 12 months predicted decreased multiple sclerosis disease activity, characterized by a 57% lower rate of new active lesions (p < 0.001), and a 25% lower 12-month increase in the T2-lesion volume (p < 0.001). Furthermore, it predicted a 57% lower relapse rate during a 4-year period, with p < 0.05 (06). 25-hydroxy vitamin D levels greater than or equal to 20 ng/mL at 12 months predicted reduced disability in subsequent months 12 through 60 as measured by the expanded disability status score of -0.17 (p = 0.004) (06). These findings were supportive of decreased serum 25-hydroxy vitamin D levels below 20 ng/mL as a risk factor for disease progression in the early stages of multiple sclerosis in patients treated with interferon beta-1b. On the other hand, an increased level of 25-hydroxy vitamin D by an increment of 20 ng/mL was associated with improved MRI findings, including decreased T2-lesion volume and decreased rate of active lesion formation in patients treated with interferon beta-1b (06). More studies are needed to look at vitamin D levels and their supportive role in treating vitamin D deficiency to improve outcome in all multiple sclerosis patients.
Cigarette smoking and exposure to secondhand smoke from tobacco are significant risk factors for multiple sclerosis. In a prospective Nurses Health study of women in the United States, women who smoked 25 or more packs a year had an increased incidence of multiple sclerosis (relative risk 1.7, 95% confidence interval 1.2-2.4, p < 0.01) (43). In a population-based case-control study in France, children with exposure to parental cigarette smoking had an adjusted relative risk of 2.12 of having multiple sclerosis (relative risk 2.1, 95% confidence interval 1.43-3.15), an effect that was greater in those with multiple sclerosis onset after 10 years of age (relative risk 2.49, 95% confidence interval 1.53-4.08) (57).
Obesity is another environmental risk factor for multiple sclerosis. A large study using cohorts from two separate Nurses’ Health Studies showed that obesity at 18 years of age doubles the risk of multiple sclerosis with a multivariate pooled relative risk of 2.25 (95% CI: 1.50–3.37, p < 0.001) (62). Childhood and adolescent obesity have been identified as a risk factor for childhood multiple sclerosis, which is similar to adults (60; 50). A case cohort study of patients from Kaiser Permanente Southern California showed that obesity was associated with an increased risk of multiple sclerosis and clinically isolated syndrome in girls 11 to 18 years of age (adjusted OR: 1.58, CI: 0.70 and 4.49 in moderately obese female children; adjusted OR: 3.76, CI: 1.54 and 9.16 for extremely obese female children; p = 0.005) (50). Although these were statistically significant results in young female children, there was no significantly increased risk for multiple sclerosis and clinically isolated syndrome in obese male children according to this study (50). A large prospective study of body mass index in children aged 7 to 13 showed that girls with a 95th or greater percentile for BMI had a 1.61- to 1.95-fold increased risk for multiple sclerosis compared with girls below the 85th percentile for BMI (p < 0.01) (60).
Many patients with multiple sclerosis have metabolic syndrome that is characterized by clinical symptomatology thought to be a risk factor for coronary artery disease, stroke, and type 2 diabetes, including elevated blood pressure, high blood sugar levels, elevated waistline area around the abdominal region, elevated triglyceride level, and low high-density lipoprotein level. Some investigators have looked at the role of treatments like metformin and pioglitazone for multiple sclerosis MRI abnormalities that may be monitored over time while on these treatments for metabolic syndrome. There was a significantly decreased number of new or enlarging T2 lesions on brain MRIs in patients treated with metformin or pioglitazone compared to controls (64). No p values were reported for these findings, but the authors noted that significance meant a p value less than 0.05 for a two-tailed test of significance in their results. The greatest reduction in the mean number of new or enlarging T2 lesions occurred at 18 months following treatment with metformin at 0.5, with a standard deviation of 0.7, and following treatment with pioglitazone at 0.6, with a standard deviation of 0.8. However, no significant differences in the annualized relapse rate or disability on the Expanded Disability Status Scale score were found at 24 months during the follow-up period between those who received metformin or pioglitazone and the control group. Nevertheless, treatment with metformin increased serum adiponectin levels, with a mean of 15.4 and a standard deviation of 5.5 micrograms/mL compared with the control group, where adiponectin levels were relatively reduced, with a mean of 4.5 and a standard deviation of 2.4 micrograms/mL, p < 0.001. Serum leptin levels were significantly decreased in those treated with metformin, with a mean of 5.5 and standard deviation of 2.5 nanograms/mL, compared with the control group, where the mean was comparably increased at 10.5 with a standard deviation of 3.4 ng/mL, p < 0.001 (64). These study results suggest that treating with metformin for metabolic syndrome in those with multiple sclerosis may influence the serum levels of adipokines, such as adiponectin. This may play an important role in obesity, which is a risk factor for multiple sclerosis in adolescents. Research on treatment for metabolic syndrome continues, and there are other studies looking at the role of metformin in patients with multiple sclerosis.
Gut microbiota in children with multiple sclerosis is different from age matched controls without multiple sclerosis, allowing some insight into the mechanism of disease close to the onset of disease (77). Different amino acid tryptophan metabolism pathways resulting in changes in the levels of distinct tryptophan metabolites may affect the incidence and disease activity of pediatric onset multiple sclerosis. Higher levels of tryptophan and indole lactate, a metabolite of tryptophan, produced by intestinal bacteria within the gut, decreased the risk of developing pediatric multiple sclerosis. Every 1 mcg/mL increase in serum tryptophan was associated with a 20% reduction in the adjusted odds of developing multiple sclerosis (95% CI: 4%-34%, p = 0.017). Furthermore, after the adjustment for age, sex, race as well as ethnicity and serum 25-hydroxy vitamin D levels, an increase in the serum tryptophan level of 1 mcg/mL was associated with a 34% reduction in the risk of developing multiple sclerosis (95% CI: 16% to 44%, p < 0.001). On the other hand, increased levels of kynurenine, which is not produced by the gut microbiota but via liver-derived enzymes, such as tryptophan 2,3-dioxygenase or indoleamine 2,3-dioxygenase enzymes, were associated with an increased relapse rate, with incident rate ratio of 5.8 (p =0.003) (35; 65).
Pathogenesis and immunobiology
Multiple sclerosis pathogenesis involves immune cell responses, such as T-cell and B-cell autoreactivity, as well as innate immune responses involving macrophages and resident central nervous system cells, such as microglia, and central nervous system involvement, including neurons, astrocytes, oligodendrocytes, axons, and their myelin sheaths (88). Differentiation between acute multiple sclerosis and acute disseminated encephalomyelitis does not appear clear-cut based on pathological findings. A retrospective cohort study of perivenous demyelination cases showed that both confluent demyelination, characteristic of acute multiple sclerosis lesions, and perivenous demyelination, typically associated with acute disseminated encephalomyelitis, were found on brain biopsy or autopsy samples in three of the 13 perivenous demyelination cases, indicating that these disorders overlap pathologically (90). The genes related to susceptibility to multiple sclerosis are various in nature and correspond to the risk for developing autoimmunity among other genes that are important for microglial activation (45). Lesions in children tend to be more inflammatory, with more edema in those lesions than those of adults (22). Diffusion tensor imaging indicates early changes in neuronal connectivity in pediatric multiple sclerosis (82).
Multiple sclerosis in children may represent a form of the disease close to its onset and, in this context, may allow insights into the pathogenesis. It is likely that the initial inflammatory CNS event occurs as a parainfectious disorder, possibly involving various infectious agents in some patients. In this context, the initial episode of CNS inflammation may occur as an episode of molecular mimicry. Subsequent episodes of inflammation arising from this parainfectious repertoire occur in individuals rendered susceptible to multiple sclerosis. There is evidence of molecular mimicry involving the Epstein-Barr virus EBNA1 and glial cell adhesion molecule. A study by a group at Stanford University showed evidence of molecular mimicry, suggesting that Epstein-Barr virus may play a causal role in the etiology of some adult-onset multiple sclerosis subsets (51). Samples from the CSF of nine patients with multiple sclerosis in age groups 16 to 20, 21 to 25, 26 to 30, 36 to 40, and 41 to 45 included antibodies directed against viruses from the largest B-cell clonal expansions associated with multiple sclerosis. They were used to create recombinant antibodies.
Using protein microarray-based studies, they were able to identify a cross-reactive antibody that recognized EBNA1 and glial cellular adhesion molecule. Proteolipid protein amino acid 139-151 experimental autoimmune encephalomyelitis mice were immunized with EBNA1 amino acid 386-405 versus scrambled control peptide. This showed that EBNA1 amino acid 386-405 increased the severity of experimental autoimmune encephalomyelitis, with worsening weakness, greater infiltration of immune cells, and worse areas of demyelination in the spinal cord. Epstein-Barr virus may play a very important role in the early stages of multiple sclerosis, as EBNA1 antibodies were found in CSF B-cell plasmablasts in nearly 25% of patients with multiple sclerosis. Additional studies may provide further insight into the development of treatments in patients with multiple sclerosis by using targeted therapies against EBNA1, as well as therapies directed against glial cell adhesion molecule found in oligodendrocytes, as there was evidence of cross-reactivity between the two proteins.
On a cellular level, there is an increased proportion of memory T cells in the setting of reduced percentages of naïve T cells in patients with pediatric-onset multiple sclerosis compared with healthy controls of the same age, which is similar to adults with multiple sclerosis (08). However, alterations in B-cell subsets during acute relapses in pediatric-onset multiple sclerosis differ from those in adult multiple sclerosis. Pediatric-onset multiple sclerosis is characterized by an increase in the proportions of plasmablasts as well as non-class switched memory B cells in the cerebrospinal fluid compared with the presence of primarily class-switched memory B cells and plasma cells in adult patients with multiple sclerosis (72). Furthermore, there are some data that suggest that cerebrospinal fluid plasmablasts are associated with increased IgG synthesis and acute central nervous system inflammation as demonstrated by an increase in the number of gadolinium-enhancing lesions on brain MRI in patients with multiple sclerosis (21). The increased percentages of cerebrospinal fluid plasmablasts in patients with pediatric-onset multiple sclerosis are consistent with the finding of increased central nervous system inflammation in childhood multiple sclerosis compared with adult multiple sclerosis.
There is a greater likelihood of finding neutrophils in the CSF of pediatric patients with multiple sclerosis 11 years of age or younger (23). Although the role of neutrophils has not been clearly defined in pediatric multiple sclerosis pathogenesis, there is some evidence from animal studies that CXCR2-positive neutrophils may be essential for mediating central nervous system demyelination in the cuprizone model of demyelination and in the animal model of experimental autoimmune encephalomyelitis (52). Furthermore, neutrophil infiltration controlled by opposing effects of IL-17 and interferon-gamma cytokines on CXCL2-induced neutrophil recruitment is necessary for brain but not spinal cord inflammation in the experimental autoimmune encephalomyelitis model (74). It is possible that neutrophils may play an important role in central nervous system demyelination and that cytokine-specific regulation of neutrophil infiltration is required for the localization of inflammation to specific regions of the central nervous system at the biological onset of multiple sclerosis.
Gray matter atrophy is associated with disability in adult multiple sclerosis (34). A study looking at cortical lesions in pediatric patients with multiple sclerosis showed that there are relatively fewer cortical lesions in pediatric patients compared to adults with multiple sclerosis (02). However, some studies have shown that pediatric patients with multiple sclerosis have significant levels of grey matter loss in the thalamus, which correlates with cognitive impairment but does not appear to be associated with physical disability as measured by the Expanded Disability Status Scale (56; 76). Acute axonal damage is increased by more than 50% in early active demyelinating lesions in pediatric patients compared to adult patients with multiple sclerosis (68).
There is some evidence that there is greater central nervous system remyelination in early versus chronic multiple sclerosis, although the mechanism through which this occurs is not well delineated (38). Abnormal central nervous system remyelination in multiple sclerosis may involve dysregulation of the Wnt pathway. Signaling through the Wnt/beta-Catenin pathway, known to be critical in anterior-posterior patterning in vertebrates, is thought to play an important role in normal developmental myelination in mammals (32). Increased levels of Wnt pathway mRNA and proteins have been found in multiple sclerosis lesions, suggesting that this pathway may also be important in inhibiting remyelination in multiple sclerosis (32). Impaired axonal regeneration in multiple sclerosis may be multifactorial, involving both extrinsic factors, including myelin-associated inhibitors such as NOGO, MAG OMgp, lipid sulfatide, and chondroitin sulfate proteoglycan; signaling pathways that may transduce inhibitory signals for axonal regeneration, and intrinsic factors that may be age-dependent (18; 67).
Clinical characteristics of multiple sclerosis in children
Most pediatric patients with multiple sclerosis have relapsing-remitting disease. A primary progressive course is rare in pediatric multiple sclerosis, unlike adult multiple sclerosis in which 10% to 15% of patients have a primary progressive course (09a). The ratio of females to males is age dependent. The gender ratio is nearly equal in children under 6 years of age, with a female to male ratio of 0.8:1; it increases to 1.6:1 in children aged 6 through 10 and then increases to 2:1 for onset after 10 years of age (09b). A prospective population-based study in South East Wales showed that the female to male ratio was 4:1 at adolescence, 2.5:1 in adults until the age of 45 to 49, and then 1:1.5 after the age of 50 (27). Exacerbations of inflammation may manifest clinically with focal neurologic deficits. Compared to adults who have multiple sclerosis, children have a more inflammatory disease course, both in terms of clinical relapse rate and inflammatory brain lesion volumes on neuroimaging. The most common initial monofocal attacks include optic neuritis and acute transverse myelitis, each accounting for about one fourth of all childhood acquired demyelinating syndrome cases (15). The size of the focal inflammatory lesions, along with the extent of the acute inflammation, appear to be a function of age, with the more severe vascular inflammation occurring in children and progressively less likelihood with increasing age (54; 07; 85). Although patients with pediatric-onset multiple sclerosis take longer to develop progressive disability compared to those who are diagnosed in adulthood, they reach progression at a younger age overall (15). The onset of progression generally occurs 10 years earlier in patients with pediatric-onset disease compared with adults (69).
The distinction between demyelinating syndromes of the central nervous system has led to five main phenotypes: (1) multiple sclerosis, (2) AQP4-positive neuromyelitis optica spectrum disorders (NMOSD), (3) myelin oligodendrocyte glycoprotein antibody-associated disorders (MOGAD), (4) autoimmune GFAP astrocytopathy, and (5) antibody-negative demyelinating syndromes. The proportion of patients positive for MOG-IgG appears to be higher in pediatric cohorts compared to adults (16; 55; 82). Furthermore, myelin oligodendrocyte glycoprotein appears to predict a disease course other than that of multiple sclerosis (40; 33). Presentations of MOGAD vary with age, with older children being more likely to present with optic neuritis or transverse myelitis, whereas acute disseminated encephalomyelitis is more common in younger children. The proportion of pediatric patients with CNS demyelinating syndrome who had anti-MOG antibodies was about one third. The percentage of these individuals who then became seronegative for the anti-MOG antibody was about 57%, typically within 1 year. This was the median time to conversion to seronegative status in a prospective multicenter cohort study conducted between 2004 and 2017 (84). About 53% of pediatric patients with CNS demyelinating syndrome who had anti-MOG antibodies had full resolution of their baseline MRI changes, and only 38% who remained seropositive for anti-MOG antibodies subsequently developed a clinical relapse, indicating that the majority of individuals with anti-MOG antibodies in this cohort study had a monophasic course of illness.
Earlier age at onset of multiple sclerosis is associated with an increased likelihood of complete recovery from an initial relapse (27). This may represent the potential for improved recovery in the context of resolution of edema. In addition, greater neural plasticity and synaptic changes may contribute to the tendency for improved recovery from acute deficits in children, at least initially. However, chronic ongoing pathological processes in children often have the potential of disrupting the developmental process. Consequently, cognitive dysfunction is frequent even in the absence of physical disability. A multicenter, cross-sectional study of 187 pediatric patients under 18 years of age with multiple sclerosis and 44 patients with clinically isolated syndrome showed that 35% of pediatric patients with multiple sclerosis and 18% of patients with clinically isolated syndrome had neuropsychological testing results consistent with cognitive impairment and highlighted problems with fine motor coordination (54%), difficulty with visual-motor integration (50%), and slowness of information processing (35%) (47). Processing speed, one of the cognitive domains that is often impacted in children with multiple sclerosis, as measured by the Symbol Digit Modalities Test, increased with age in patients with childhood multiple sclerosis and then decreased over time in these patients (03). Furthermore, the prevalence of seizures in patients with multiple sclerosis was 3% to 4%, based on six population-based studies (48). Onset of multiple sclerosis earlier than 16 years of age (p = 0.01) and increased mean Expanded Disability Status Scale Score (p = 0.004) were both associated with an increased likelihood of having seizures (29). It is possible that the prevalence of seizures in pediatric-onset multiple sclerosis may be higher than in the adult population (29), but further research on this topic is needed.
Clinical applications
Monitoring of clinical disease activity and the use of effective immune-based therapies are important for preventing long-term disability in patients with multiple sclerosis. Consequently, delays in treatment with disease-modifying drugs may contribute to the greater number of relapses in pediatric multiple sclerosis compared to adults. However, a study demonstrated that pediatric patients with multiple sclerosis have a greater number of relapses than adult patients with multiple sclerosis after controlling for treatment with disease-modifying medications, suggesting that there may be increased central nervous system inflammation in pediatric patients compared with adults with multiple sclerosis (39).
Treatment options for acute exacerbations are the same in both pediatric patients and adults with multiple sclerosis, with the use of intravenous corticosteroids as first-line therapy and the addition of plasmapheresis for patients with acute exacerbations that are refractory to intravenous corticosteroids.
Though some have used IVIG for the treatment of acute exacerbations in pediatric patients with multiple sclerosis, the majority of the literature suggests that adult patients with multiple sclerosis have no benefit from IVIG for an acute relapsing event.
In the past 20 years, several disease-modifying therapies have been approved for the treatment of multiple sclerosis in adults. Historically, phase 3 studies of disease-modifying therapies in patients with multiple sclerosis have not included patients below the age of 18, and most therapies in pediatric-onset multiple sclerosis are prescribed off-label, relying on adult multiple sclerosis studies and protocols. There is considerably less information regarding the efficacy and safety of immune-based agents in children compared to adults with multiple sclerosis. The challenges regarding clinical trials in pediatric-onset multiple sclerosis include the low incidence and prevalence of pediatric-onset multiple sclerosis, difficulty in recruiting and enrolling a sufficiently high number of children, and emphasis on exclusion of other mimics, particularly myelin oligodendrocyte glycoprotein and aquaporin-4 antibody associated disorders (01). In recent years, several randomized clinical trials on therapies for pediatric-onset multiple sclerosis have been published.
In 2012, the International Pediatric Multiple Sclerosis Study Group guidelines recommended the use of interferon beta or glatiramer acetate as first-line therapy (41). Since then, there has been some evidence that favors the use of newer, highly effective disease-modifying medications, such as fingolimod, teriflunomide, natalizumab, and dimethyl fumarate, as first-line treatment for pediatric-onset multiple sclerosis based on clinical trials and an observational study (49; 41). Fingolimod became the first disease-modifying therapy specifically indicated for pediatric-onset multiple sclerosis when it was FDA approved in 2018 for the treatment of children 10 years and older with relapsing-remitting multiple sclerosis. Its approval was based on the results of the landmark PARADIGMS study, a phase 3, double-blind clinical trial of 215 pediatric patients with multiple sclerosis that compared fingolimod to interferon beta-1a. The results showed that treatment with fingolimod for up to 2 years reduced the annualized relapse rate (adjusted ARR: 0.12 vs. 0.67; P < 0.001) and annual new or newly enlarged T2-weighted MRI lesions (4.39 vs. 9.27; P < 0.001) compared to interferon beta-1a, including in treatment-naive and younger patients (25). There were a significant number of mild adverse events, such as leukopenia and infections, that occurred in the individuals treated with fingolimod. A few individuals had seizures, which appears to be unique to the pediatric population (15).
TERIKIDS was a phase 3, randomized, double-blind clinical trial that assessed the safety and efficacy of teriflunomide compared to placebo in patients between the ages of 10 and 17 diagnosed with pediatric-onset multiple sclerosis. The study enrolled 166 patients across 57 centers and lasted nearly 96 weeks in most of the patients. A significant number of individuals switched to the 192-week open-label extension trial period, in which all patients received teriflunomide prior to completing the entire duration of the 96-week double-blind study. This switch was possibly due to the high MRI activity discovered during the trial and may have led to a reduction of the power in the study results as well as the lack of a statistically significant difference between the two groups in the primary endpoint: time to first confirmed clinical relapse. The hazard ratio was 0.66, with a 95% confidence interval of 0.388 to 1.113, p = 0.29. Nevertheless, the secondary endpoint results indicated a reduction in the number of new or expanding T2-weighted lesions on MRI, with a relative risk ratio of 0.45 and 95% confidence interval of 0.29 to 0.71, p = 0.00061. This secondary endpoint finding led to the approval of teriflunomide for use in pediatric multiple sclerosis in European countries but not in the United States due to safety concerns; specifically, the trial showed various adverse events, including an increase in acute pancreatitis requiring at least two to three individuals to stop their study treatment (26).
The CONNECT study was an open-label, randomized, rater-blinded, active-controlled, phase 3 clinical trial that compared dimethyl fumarate with interferon beta-1a during a 96-week period in patients between 10 and 17 years of age diagnosed with pediatric-onset multiple sclerosis. It enrolled 150 patients in various centers throughout the world. The trial demonstrated that the annualized rate of relapse was 0.24 at 96 weeks, with a 95% confidence interval of 0.15 to 0.39 in those patients treated with dimethyl fumarate, compared with an annualized relapse rate of 0.53, with a 95% confidence interval of 0.33 to 0.84, for interferon beta. This resulted in a rate ratio of 0.46, with a 95% confidence interval of 0.26 to 0.80, p = 0.006, for dimethyl fumarate compared with interferon beta-1a. However, the hazard ratio for risk of relapse for dimethyl fumarate compared with interferon beta-1a was not statistically significant, p > 0.05.
Other secondary endpoints included the number of T2 lesions and proportion of patients who were relapse free. Of those treated with dimethyl fumarate who completed the trial, 16.1% (95% CI: 8% to 27.7%) had no newly enlarging or new T2 hyperintense lesions, whereas only 4.9% (95% CI: 0.6% to 16.5%) of those treated with interferon beta-1b had none of these types of MRI findings. The study did not have sufficient power to detect statistically significant differences between these two groups. Approximately 66.2% of those treated with dimethyl fumarate were relapse free at 96 weeks compared with 52.3% in those treated with interferon beta-1a. No major differences were noted for the number of treatment-emergent adverse events between the two groups (81).
Natalizumab has been used to treat pediatric multiple sclerosis refractory to first-line disease-modifying therapies. Based on the experience of 24 pediatric patients with multiple sclerosis in a network of pediatric multiple sclerosis centers in the United States, the majority of patients showed good response to natalizumab after 18 months of treatment based on MRI and clinical measures of disease activity (89). A prospective cohort study of 55 pediatric patients with multiple sclerosis in Italy receiving a median of 26 monthly infusions of natalizumab showed that the mean expanded disability status scale score decreased from 2.7 to 1.9 (p < 0.0001). The majority of patients developed no new T2 or gadolinium enhancing lesions on MRI; and clinical adverse effects were relatively mild. Although 20 out of 51 patients were positive for the JCV antibody, there were no confirmed cases of progressive multifocal leukoencephalopathy (37). Although it is possible that pediatric patients with multiple sclerosis have a lower risk of developing progressive multifocal leukoencephalopathy than adults, further studies are necessary to determine the risk of progressive multifocal leukoencephalopathy in children with multiple sclerosis.
A small, retrospective study evaluating rituximab, a chimeric monoclonal antibody targeting CD20 on B cells, for treatment in eight patients with NMOSD and three patients with pediatric-onset multiple sclerosis showed major improvement in reducing relapses in nine of 11 patients, including two patients with pediatric-onset multiple sclerosis who remained relapse free on follow-up. This finding suggested that targeting B cells may be efficacious in preventing relapses (11; 36). Rituximab is the only B-cell depletion therapy that has been approved by the FDA (December 2021) for the treatment of B-cell lymphomas and leukemia in pediatric patients between 6 months and 18 years of age, placing this drug in the treatment armamentarium for pediatric-onset multiple sclerosis. There is currently a phase 3 clinical trial evaluating the safety and efficacy of ocrelizumab compared to fingolimod in pediatric patients aged 10 to 17 with multiple sclerosis (15). Ocrelizumab is a humanized monoclonal antibody directed against CD20, a marker for B cells, and is given as an intravenous infusion every 24 weeks compared to fingolimod, which is taken daily orally.
Although treatment monitoring with biomarkers such as neurofilament may be used in the future for various disorders, including neurodegenerative disorders such as Alzheimer disease, there is a need for a new biomarker for predicting progression to secondary progressive disease or primary progressive disease in pediatric-onset multiple sclerosis, such as slowly expanding lesions, which determine the progression of multiple sclerosis in patients with relapsing-remitting multiple sclerosis (31; 20). Slowly expanding lesions on MRI may be a biomarker for prognostication in relapsing-remitting pediatric patients in the future.
The relapsing-remitting course of multiple sclerosis in childhood may be slower compared to adults. A natural history study of pediatric multiple sclerosis showed that the time to secondary progression is longer in children compared to adults with multiple sclerosis, although age at onset of secondary progression was earlier in pediatric patients with multiple sclerosis (69). The slower course of pediatric multiple sclerosis may, in part, be due to greater potential for central nervous system remyelination and axonal regeneration in children compared to adults with multiple sclerosis. However, it is unclear whether repair and growth are the main causes for the slow progressive nature of pediatric-onset multiple sclerosis. The presence of edema, which may resolve quickly in the central nervous system in childhood-onset multiple sclerosis, may correlate with the disappearance of MRI lesions in this group of patients (22). Furthermore, the relative lack of physical disability in pediatric multiple sclerosis compared with adult multiple sclerosis may be associated with the relative lack of cortical lesions in pediatric multiple sclerosis (02).
Multiple sclerosis is considered rare in children, in part, because it is underdiagnosed and often mistaken for other diseases mimicking multiple sclerosis. Furthermore, age-dependent changes in the immune responses to environmental triggers and greater plasticity of the developing target central nervous system in children may also contribute to the decreased incidence of pediatric compared to adult multiple sclerosis. Modifying risk factors in childhood through the supplementation of vitamin D, immunization by vaccination against Epstein-Barr virus, and treatment with anti–Epstein-Barr virus therapies, B-cell depletion therapies that are effective in controlling Epstein-Barr virus infection, in addition to promoting tobacco cessation, weight reduction to prevent obesity, and dietary changes to modify the gut microbiome to decrease central nervous system inflammation, are potential strategies that could be developed to prevent multiple sclerosis and augment current treatment strategies of reducing central nervous system inflammation to stop further disease activity and progression.
References
- 01
- Abdel-Mannan O, Ciccarelli O, Hacohen Y. Considering the future of pediatric multiple sclerosis trials after the CONNECT open-label randomized trial. JAMA Netw Open 2022;5(9):e2230451. PMID 36169961
- 02
- Absinta M, Rocca MA, Moiola L, et al. Cortical lesions in children with multiple sclerosis. Neurology 2011;76(10):910-3. PMID 21383327
- 03
- Akbar N, Signori A, Amato MP, et al. Maturational trajectory of processing speed performance in pediatric multiple sclerosis. Dev Neuropsychol 2017;42(5):299-308. PMID 28872902
- 04
- Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 2007a;61(4):288-99. PMID 17444504
- 05
- Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol 2007b;61(6):504-13. PMID 17492755
- 06
- Ascherio A, Munger KL, White R, et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol 2014;71(3):306-14. PMID 24445558
- 07
- Balassy C, Bernert G, Wober-Bingol C, et al. Long-term MRI observations of childhood-onset relapsing-remitting multiple sclerosis. Neuropediatrics 2001;32(1):28-37. PMID 11315199
- 08
- Balint B, Haas J, Schwarz A, et al. T-cell homeostasis in pediatric multiple sclerosis: old cells in young patients. Neurology 2013;81(9):784-92. PMID 23911752
- 09
- Banwell B, Ghezzi A, Bar-Or A, Mikaeloff Y, Tardieu M. Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol 2007b;6(10):887-902. PMID 17884679
- 10
- Banwell B, Krupp L, Kennedy J, et al. Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol 2007a;6(9):773-81. PMID 17689148
- 11
- Beres SJ, Graves J, Waubant E. Rituximab use in pediatric central demyelinating disease. Pediatric Neurol 2014;51(1):114-8. PMID 24768216
- 12
- Bjornevik K, Cortese M, Healy B, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science 2022;375(6578):296-301. PMID 35025605
- 13
- Boiko AN, Gusev EI, Sudomoina MA, et al. Association and linkage of juvenile MS with HLA-DR2(15) in Russians. Neurology 2002;58(4):658-60. PMID 11865153
- 14
- Boman J, Roblin PM, Sundstrom P, Sandstrom M, Hammerschlag MR. Failure to detect Chlamydia pneumoniae in the central nervous system of patients with MS. Neurology 2000;54(1):265. PMID 10636169
- 15
- Brenton JN. Pediatric acquired demyelinating disorders. Continuum (Minneap Minn) 2022;28(4):1104-30. PMID 35938659
- 16
- Brilot F, Dale RC, Selter RC, et al. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol 2009;66(6):833-42. PMID 20033986
- 17
- Burrell AM, Handel AE, Ramagopalan SV, Ebers GC, Morahan JM. Epigenetic mechanisms in multiple sclerosis and the major histocompatibility complex (MHC). Discov Med 2011;11(58):187-96. PMID 21447278
- 18
- Cai D, Qiu J, Cao Z, McAtee M, Bregman BS, Filbin MT. Neuronal cyclic AMP controls the developmental loss in ability of axons to regenerate. J Neurosci 2001;21(13):4731-9. PMID 11425900
- 19
- Calabrese M, Rinaldi F, Mattisi I, et al. The predictive value of gray matter atrophy in clinically isolated syndromes. Neurology 2011;77(3):257-63. PMID 21613600
- 20
- Calvi A, Carrasco FP, Tur C, et al. Association of slowly expanding lesions on MRI with disability in people with secondary progressive multiple sclerosis. Neurology 2022;98(17):e1783-93. PMID 35277438
- 21
- Cepok S, Rosche B, Grummel V, et al. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 2005;128(Pt 7):1667-76. PMID 15800022
- 22
- Chabas D, Castillo-Trivino T, Mowry EM, Strober JB, Glenn OA, Waubant E. Vanishing MS T2-bright lesions before puberty: a distinct MRI phenotype. Neurology 2008;71(14):1090-3. PMID 18824673
- 23
- Chabas D, Ness J, Belman A, et al. Younger children with MS have a distinct CSF inflammatory profile at disease onset. Neurology 2010;74(5):399-405. PMID 20124205
- 24
- Chao MJ, Barnardo MC, Lincoln MR, et al. HLA class I alleles tag HLA-DRB11501 haplotypes for differential risk in multiple sclerosis susceptibility. Proc Natl Acad Sci U S A 2008;105(35):13069-74. PMID 18765817
- 25
- Chitnis T, Arnold DL, Banwell B, et al. Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis. N Engl J Med 2018;379(11):1017-27. PMID 30207920
- 26
- Chitnis T, Banwell B, Kappos L, et al. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial. Lancet Neurol 2021;20(12):1001-11. PMID 34800398
- 27
- Cossburn M, Ingram G, Hirst C, Ben-Shlomo Y, Pickersgill TP, Robertson NP. Age at onset as a determinant of presenting phenotype and initial relapse recovery in multiple sclerosis. Mult Scler 2012;18(1):45-54. PMID 21865412
- 28
- Disanto G, Magalhaes S, Handel AE, et al. HLA-DRB1 confers increased risk of pediatric-onset MS in children with acquired demyelination. Neurology 2011;76(9):781-6. PMID 21288988
- 29
- Durmus H, Kurtuncu M, Tuzun E, et al. Comparative clinical characteristics of early- and adult-onset multiple sclerosis patients with seizures. Acta Neurol Belg 2013;113(4):421-6. PMID 23696071
- 30
- Dutta R, Chang A, Doud MK, et al. Demyelination causes synaptic alterations in hippocampi from multiple sclerosis patients. Ann Neurol 2011;69(3):445-54. PMID 21446020
- 31
- Elliott C, Wolinsky JS, Hauser SL, et al. Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions. Mult Scler 2019;25(14):1915-25. PMID 30566027
- 32
- Fancy SP, Baranzini SE, Zhao C, et al. Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS. Genes Dev 2009;23(13):1571-85. PMID 19515974
- 33
- Fernandez-Carbonell C, Vargas-Lowy D, Musallam A, et al. Clinical and MRI phenotype of children with MOG antibodies. Mult Scler 2016;22(2):174-84. PMID 26041801
- 34
- Fisher E, Lee JC, Nakamura K, Rudick RA. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 2008;64(3):255-65. PMID 18661561
- 35
- Geng J, Liu A. Heme dependent deoxygenates in tryptophan oxidation. Arch Biochem Biophys 2014;544:18-26. PMID 24295960
- 36
- Ghezzi A, Banwell B, Bar-Or A, et al. Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: practical considerations. Mult Scler 2021;27(12):1814-22. PMID 32552353
- 37
- Ghezzi A, Pozzilli C, Grimaldi LM, et al. Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. Mult Scler 2013;19(8):1106-12. PMID 23401129
- 38
- Goldschmidt T, Antel J, Konig FB, Bruck W, Kuhlmann T. Remyelination capacity of the MS brain decreases with disease chronicity. Neurology 2009;72(22):1914-21. PMID 19487649
- 39
- Gorman MP, Healy BC, Polgar-Turcsanyi M, Chitnis T. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol 2009;66(1):54-9. PMID 19139299
- 40
- Hacohen Y, Absoud M, Deiva K, et al. Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children. Neurol Neuroimmunol Neuroinflamm 2015;2(2):e81. PMID 25798445
- 41
- Hacohen Y, Banwell B, Ciccarelli O. What does first-line therapy mean for paediatric multiple sclerosis in the current era? Mult Scler 2021;27(13)1970-6. PMID 32633605
- 42
- Henderson AP, Barnett MH, Parratt JD, Prineas JW. Multiple sclerosis: distribution of inflammatory cells in newly forming lesions. Ann Neurol 2009;66(6):739-53. PMID 20035511
- 43
- Hernan MA, Olek MJ, Ascherio A. Cigarette smoking and incidence of multiple sclerosis. Am J Epidemiol 2001;154(1):69-74. PMID 11427406
- 44
- International Multiple Sclerosis Genetics Consortium, Hafler DA, Compston A, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007;357(9):851-62. PMID 17660530
- 45
- International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science 2019;365(6460):eaav7188. PMID 31604244
- 46
- International Multiple Sclerosis Genetics Consortium, Sawcer S, Hellenthal G, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011;476(7359):214-9. PMID 21833088
- 47
- Julian L, Serafin D, Charvet L, et al. Cognitive impairment occurs in children and adolescents with multiple sclerosis: results from a United States network. J Child Neurol 2013;28(1):102-7. PMID 23155206
- 48
- Kelley BJ, Rodriguez M. Seizures in patients with multiple sclerosis: epidemiology, pathophysiology and management. CNS Drugs 2009;23(10):805-15. PMID 19739692
- 49
- Krysko KM, Graves J, Rensel M, et al. Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US. Neurology 2018;91(19):e1778-87. PMID 30333163
- 50
- Langer-Gould A, Brara SM, Beaber BE, Koebnick C. Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome. Neurology 2013;80(6):548-52. PMID 23365063
- 51
- Lanz TV, Brewer RC, Ho PP, et al. Clonal expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature 2022;603(7900):321-7. PMID 35073561
- 52
- Liu L, Belkadi A, Darnall L, et al. CXCR2-positive neutrophils are essential for cuprizone-induced demyelination: relevance to multiple sclerosis. Nat Neurosci 2010;13(3):319-26. PMID 20154684
- 53
- Lucchinetti CF, Popescu BF, Bunyan RF, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 2011;365(23):2188-97. PMID 22150037
- 54
- Mattyus A, Veres E. Multiple sclerosis in childhood: long term katamnestic investigations. Acta Paediatr Hung 1985;26(3):193-204. PMID 4084409
- 55
- McLaughlin KA, Chitnis T, Newcombe J, et al. Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol 2009;183(6):4067-76. PMID 19687098
- 56
- Mesaros S, Rocca, MA, Absinta M, et al. Evidence of thalamic gray matter loss in pediatric multiple sclerosis. Neurology 2008;70(13 Pt 2):1107-12. PMID 18272867
- 57
- Mikaeloff Y, Caridade G, Tardieu M, Suissa S; KIDSEP study group. Parental smoking at home and the risk of childhood-onset multiple sclerosis in children. Brain 2007;130(Pt 10):2589-95. PMID 17827175
- 58
- Montgomery S, Hajiebrahimi M, Burkill S, Hillert J, Olsson T, Bahmanyar S. Multiple sclerosis and risk of young-adult-onset Hodgkin lymphoma. Neurol Neuroimmunol Neuroinflamm 2016;3(3):e227. PMID 27144218
- 59
- Mowry EM, Krupp LB, Milazzo M, et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol 2010;67(5):618-24. PMID 20437559
- 60
- Munger KL. Childhood obesity is a risk factor for multiple sclerosis. Mult Scler 2013;19(13):1800. PMID 24072725
- 61
- Munger KL, Bentzen J, Lauren B, et al. Childhood body mass index and multiple sclerosis risk: a long-term cohort study. Mult Scler 2013;19(10):1323-9. PMID 23549432
- 62
- Munger KL, Chitnis T, Ascherio A. Body size and risk of MS in two cohorts of US women. Neurology 2009;73(19):1543-50. PMID 19901245
- 63
- Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006;296(23):2832-8. PMID 17179460
- 64
- Negrotto L, Farez MF, Correale J. Immunologic effects of metformin and pioglitazone treatment on metabolic syndrome and multiple sclerosis. JAMA Neurol 2016;73(5):520-8. PMID 26953870
- 65
- Nourbakhsh B, Bhargava P, Tremlett H, Hart J, Graves J, Waubant E. Altered tryptophan metabolism is associated with pediatric multiple sclerosis risk and course. Ann Clin Transl Neurol 2018;5(10):1211-21. PMID 30349856
- 66
- Oksenberg JR, Barcellos LF, Cree BA, et al. Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am J Hum Genet 2004;74(1):160-7. PMID 14669136
- 67
- Petratos S, Ozturk E, Azari MF, et al. Limiting multiple sclerosis related axonopathy by blocking Nogo receptor and CRMP-2 phosphorylation. Brain 2012;135(Pt 6):1794-818. PMID 22544872
- 68
- Pfeifenbring S, Bunyan RF, Metz I, et al. Extensive acute axonal damage in pediatric multiple sclerosis lesions. Ann Neurol 2015;77(4):655-67. PMID 25612167
- 69
- Renoux C, Vukusic S, Mikaeloff Y, et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med 2007;356(25):2603-13. PMID 17582070
- 70
- Rostasy K, Reiber H, Pohl D, et al. Chlamydia pneumoniae in children with MS: frequency and quantity of intrathecal antibodies. Neurology 2003;61(1):125-8. PMID 12847174
- 71
- Ruggieri M, Plasmatti I, Simone I. Epidemiology of pediatric multiple sclerosis: incidence, prevalence and susceptibility risk factors. In: Demyelinating disorders of the central nervous system in childhood. New York: Cambridge University Press, 2011.
- 72
- Schwarz A, Balint B, Korporal-Kuhnke M, et al. B-cell populations discriminate between pediatric- and adult-onset multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2016;4(1):e309. PMID 28053999
- 73
- Shen S, Sandoval J, Swiss VA, et al. Age-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiency. Nat Neurosci 2008;11(9):1024-34. PMID 19160500
- 74
- Simmons SB, Liggitt D, Goverman JM. Cytokine-regulated neutrophil recruitment is required for brain but not spinal cord inflammation during experimental autoimmune encephalomyelitis. J Immunol 2014;193(2):555-63. PMID 24913979
- 75
- Spelman T, Simoneau G, Hyde R, et al. Comparative effectiveness of natalizumab, fingolimod, and injectable therapies in pediatric-onset multiple sclerosis: a registry-based study. Neurology 2024;102(7):e208114. PMID 38447093
- 76
- Till C, Ghassemi R, Aubert-Broche B, et al. MRI correlates of cognitive impairment in childhood-onset multiple sclerosis. Neuropsychology 2011;25(3):319-32. PMID 21534686
- 77
- Tremlett H, Fadrosh DW, Faruqi, AA, et al. Gut microbiota in early pediatric multiple sclerosis: a case-control study. Eur J Neurol 2016;23(8):1308-21. PMID 27176462
- 78
- van Pelt ED, Mescheriakova JY, Makhani N, et al. Risk genes associated with pediatric-onset MS but not with monophasic acquired CNS demyelination. Neurology 2013;81(23):1996-2001. PMID 24198294
- 79
- Vercellino M, Masera S, Lorenzatti M, et al. Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter. J Neuropathol Exp Neurol 2009;68(5):489-502. PMID 19525897
- 80
- Vercellino M, Plano F Votta B, Mutani R, Giordana MT, Cavalla P. Grey matter pathology in multiple sclerosis. J Neuropathol Exp Neurol 2005;64(12):1101-7. PMID 16319720
- 81
- Vermersch P, Scaramozza M, Levin S, et al. Effect of dimethyl fumarate vs interferon B-1a in patients with pediatric-onset multiple sclerosis: the CONNECT randomized clinical trial. JAMA Netw Open 2022;5(9):e2230439. PMID 36169959
- 82
- Vishwas MS, Healy BC, Pienaar R, Gorman MP, Grant PE, Chitnis T. Diffusion tensor analysis of pediatric multiple sclerosis and clinically isolated syndromes. AJNR Am J Neuroradiol 2013;34(2):417-23. PMID 22859275
- 83
- Walton C, King R, Rechtman, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler 2020;26(14):1816-21. PMID 33174475
- 84
- Waters P, Fadda G, Woodhall M, et al. Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes. JAMA Neurol 2020;77(1):82-93. PMID 31545352
- 85
- Waubant E, Chabas D, Okuda DT, et al. Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults. Arch Neurol 2009;66(8):967-71. PMID 19667217
- 86
- Waubant E, Lucas R, Mowry E, et al. Environmental and genetic risk factors for MS: an integrated review. Ann Clin Transl Neurol 2019;6(9):1905-22. PMID 31392849
- 87
- Waubant E, Mowry EM, Krupp L, et al. Common viruses associated with lower pediatric multiple sclerosis risk. Neurology 2011;76(23):1989-95. PMID 21646624
- 88
- Weiner HL. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease. Ann Neurol 2009;65(3):239-48. PMID 19334069
- 89
- Yeh EA, Weinstock-Guttman B. Natalizumab in pediatric multiple sclerosis patients. Ther Adv Neurol Disord 2010;3(5):293-9. PMID 21179619
- 90
- Young NP, Weinshenker BG, Parisi JE, et al. Perivenous demyelination: association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosis. Brain 2010;133(Pt 2):333-48. PMID 20129932
- 91
- Ziaei A, Solomon O, Casper T, et al. Gene-environment interactions: Epstein-Barr virus infection and risk of pediatric-onset multiple sclerosis. Mult Scler 2024;30(3)308-15. PMID 38332747
Contributors
All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.
Author
-
Moon Hee Hur MD
Dr. Hur of the University of Chicago Medical Center has no relevant financial relationships to disclose.
See Profile
Editor
-
Anthony T Reder MD
Dr. Reder of the University of Chicago received honorariums from Biogen Idec, Genentech, Genzyme, and TG Therapeutics for service on advisory boards and as a consultant and stock options from NKMax America for advisory work.
See Profile
Former Authors
- Widad Abou Chaar MD
- Susan S Kim MD PhD
- Mark A Agius MD
This is an article preview.
Start a Free Account
to access the full version.
-
Nearly 3,000 illustrations, including video clips of neurologic disorders.
-
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
-
Full spectrum of neurology in 1,200 comprehensive articles.
-
Listen to MedLink on the go with Audio versions of each article.
Questions or Comment?
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Also in This Category
-
-
Neuroimmunology
Anti-IgLON5 disease
Oct. 10, 2024
-
Infectious Disorders
Zika virus: neurologic complications
Oct. 08, 2024
-
Neuro-Oncology
Anti-LGI1 encephalitis
Oct. 03, 2024
-
General Child Neurology
Cerebral edema in childhood
Sep. 29, 2024
-
Neuro-Ophthalmology & Neuro-Otology
Giant cell arteritis
Sep. 25, 2024
-
Neuro-Oncology
CNS germinoma
Sep. 25, 2024
-
Developmental Malformations
Vein of Galen malformations
Sep. 22, 2024